Fig. 3: YY1 protects against AKI in vitro and in vivo.
From: A renal YY1-KIM1-DR5 axis regulates the progression of acute kidney injury
a, b MTT assays to assess the effects of YY1 overexpression (a) and eudesmin treatment (b) in HK-2 cells with/without 24 h cisplatin (Cis). Vec, pRK-3′HA; YY1, pRK-YY1-3′HA; CT, without cisplatin treatment. a n = 4 biological samples per group; b n = 3 biological samples per group, each experiment was repeated at least three times independently with similar results obtained. c qPCR analysis of IL6 and CXCL2 expression in YY1 overexpressing groups with/without 24 h cisplatin. n = 3 biological samples per group, each experiment was repeated at least three times independently with similar results obtained. d, e MTT assays (d) and qPCR analysis of IL6 and CXCL2 expression (e) in YY1 knockdown HK-2 cells with/without cisplatin injury. Vec, pRK-3′HA; YY1, pRK-YY1-3′HA; pSuper, pSuper backbone; shYY1, pSuper-shYY1; CT, without cisplatin treatment. d, e n = 3 biological samples per group, each experiment was repeated at least three times independently with similar results obtained. d two-tailed unpaired Student’s t-test was used. f, g qPCR (f) and Western blots (g) of KIM1 and YY1 in mouse kidneys at Day 3 after cisplatin injury with/without eudesmin treatment. f n = 4 mice per group; two-tailed unpaired Student’s t-test was used. g n = 3 mice per group. h–j Serum creatinine level (h), serum urea nitrogen level (i) and pathological score (j) in mice at Day 3 after cisplatin injury with/without eudesmin treatment. Scale bar, 50 μm. h–j n = 4 mice per group; Data shown as mean ± SD. Two-tailed unpaired Student’s t-test was used for two experimental groups, and one-way ANOVA for multiple experimental groups without adjustment. *P < 0.05; **P < 0.01. Exact P values are provided in Source Data.
